Avalo Therapeutics (AVTX) vs Lexicon Pharmaceuticals (LXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lexicon Pharmaceuticals (LXRX) has outperformed Avalo Therapeutics (AVTX) over the past year, gaining 15.8% versus a loss of 5.6%. Over five years, LXRX leads with a -71.4% price change compared with -99.8% for AVTX. Lexicon Pharmaceuticals is the larger company by market cap ($783.1 million vs $720.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVTX | LXRX |
|---|---|---|
| Share price | $13.43 | $1.76 |
| Market cap | $720.25M | $783.12M |
| 1-day change | -1.10% | 0.00% |
| YTD return | -26.05% | +53.04% |
| 1-year return | -5.56% | +15.79% |
| 5-year return | -99.79% | -71.43% |
| EPS (TTM) | $-4.31 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.27 | $2.68 |
| 52-week low | $12.51 | $1.10 |
| Distance from 52-week high | -44.66% | -34.33% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +228.22% | +158.52% |
| Average volume | 926.15K | 2.87M |
| Shares outstanding | 53.63M | 444.96M |
| Employees | 33 | 81 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LXRX has outperformed AVTX by 21.3 percentage points over the past year.
About Avalo Therapeutics
AVTX stock →Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About Lexicon Pharmaceuticals
LXRX stock →Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees
AVTX vs LXRX FAQ
Which is bigger, Avalo Therapeutics or Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals (LXRX) is larger, with a market capitalization of $783.12M compared with $720.25M for Avalo Therapeutics (AVTX).
Which stock has performed better over the past year, AVTX or LXRX?
LXRX returned +15.79% over the past 12 months, compared with -5.56% for AVTX (price return, excluding dividends). Past performance does not predict future results.
Are Avalo Therapeutics and Lexicon Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.